Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Wipro Lt 559.50 3.82
Tata Stl 458.95 0.40
Tata Pow 88.00 0.28
Ong Corp 403.25 0.80
Hindalco 149.65 0.81
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Cipla Limited
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
09-OCT-14 Cipla, leading drug maker today announced that Medpro Pharmaceutica, a subsidiary of the Cipla Medpro has entered into collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries. The collaboration is restricted to the territory of South Africa. 08-OCT-14 India Ratings & Research (Ind-Ra) has affirmed Cipla (Cipla) long-term issuer rating at 'AAA' with a stable outlook. Ind-Ra has also affirmed the compan...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Cipla gains after collaboration with Teva Pharma  -IRIS 09-Oct-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 24015.2090349.5080153.70
Other Income372.802802.802291.30
Total Income24388.0093152.3082445.00
Cost of goods sold19419.3073907.6060832.80
OPBDIT4968.7019244.7021612.20
PAT3321.7013883.4015071.10
Gross Block---
Equity capital1605.801605.801605.80
EPS (Rs.)-17.2918.77
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-21.06 - 26.0316.02 - 23.18
Debt / Equity (x)---
Operating margin (% of OI)20.420.726.2
Net margin (% of OI)13.614.918.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Mumbai Central
Mumbai
Maharashtra-400 008
PHONE
(022) 2309 5521 / 2302 5272
FAX
(022) 2300 8101
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer